Susquehanna International Group, LLP Protalix Bio Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $568 Billion
- Q1 2025
A detailed history of Susquehanna International Group, LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 858,650 shares of PLX stock, worth $2.59 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
858,650Holding current value
$2.59 Million% of portfolio
0.0%Shares
13 transactions
Others Institutions Holding PLX
# of Institutions
58Shares Held
6.65MCall Options Held
217KPut Options Held
16K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$3.59 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$2.07 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0615KShares$1.86 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.483KShares$1.46 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny388KShares$1.17 Million0.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $150M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...